Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giovanni Graziano has a total of 166 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes

    by Jhonny Azuaje, Rubén Prieto-DíaZ, Claudia Gioé-Gallo, Sandra Ortigueira, Jacobo Soilán, Diego TriñaNes, Hugo Fojo, María I. Loza, Marialessandra Contino, Maria Grazia Perrone, et al.

    The antagonism of cannabinoid 1 receptor (CB1R) signaling has demonstrated clinical efficacy in treating obesity, improving insulin resistance, enhancing cardiovascular health, and mitigating metabolic risk factors in humans. Despite these positive outcomes, the clinical use of rimonabant was limited by severe central nervous system adverse effects, which reduced interest in CB1R and hindered the exploration of new therapeutic opportunities. Selective targeting of peripheral CB1R represents a promising strategy to overcome these limitations, creating therapeutic opportunities not only for obesity and metabolic disorders but also for smoking and alcohol addiction. Herein, we report a library of 53 novel, potent, and subtype-selective CB1R antagonists bearing polar groups, designed through convergent Ugi-based synthetic pathways. This approach enabled the identification of key structure–activity relationship features within this series and the effective modulation of molecular properties governing blood–brain barrier permeability. Among the compounds evaluated, the piperazine-1-ium derivative 24a stands out as the first permanently charged CB1R antagonist, exhibiting nanomolar affinity (Ki = 115 nM) and high CB1R/CB2R selectivity with a favorable physicochemical profile consistent with peripheral restriction and limited blood-brain barrier penetration. Importantly, 24a exhibits robust functional activity in a biologically relevant model of metabolic dysfunction. In insulin-resistant, lipid-hypertrophied adipocytes, 24a restores insulin-stimulated Akt phosphorylation and significantly enhances lipolytic activity, with effects comparable or superior to those of rimonabant at equivalent concentrations. These findings establish 24a as a promising peripherally restricted CB1R antagonist with demonstrated functional efficacy in a metabolic disease-relevant cellular model.

  • Design and Development of New Dual Target Agents, Cannabinoid Subtype 2 Receptor (CB2R) Agonists, and Fatty Acid Amide Hydrolase (FAAH) Inhibitors against Neurodegeneration

    by Giovanni Graziano, Francesco Mastropasqua, Annalisa Fanizzi, M. Giovanna E. Papadopoulos, Antonio Laghezza, Mariachiara Mammone, Gabriella Rosanna Musillo, Giuseppe Felice Mangiatordi, Jose Brea, Maria Isabel Loza, et al.

    As dual modulators of Cannabinoid subtype 2 receptor (CB2R) and fatty acid amide hydrolase (FAAH)an arising therapeutic strategy against diseases based on neuroinflammationwe developed a new series of N-adamantyl-benzamides bearing an anthranilic or salicylic scaffold. Derivatives 18, 22, and 25 emerged as an interesting compromise in terms of CB2R activity, CB2R/CB1R selectivity, and FAAH inhibition. All compounds were potent FAAH inhibitors; 18 and 25 acted as unbiased CB2R agonists with no CB1R affinity, whereas 22 was a CB2R antagonist in the cAMP pathway and partial agonist in β-arrestin-2 recruitment. The three compounds were tested in monocytes and macrophages in resting and activated states and in a human activated microglia model with a potent anti-inflammatory action. These results support the CB2R and FAAH engagement as a promising dual strategy against neuroinflammation providing valuable chemical tools for probing the structural determinants underlying CB2R binding, long residence time, and biased signaling.

  • Open Access

    N-Adamantyl-1-Pentyl-4-Oxo-1,4-Dihydroquinoline-3-Carboxamide and N-(Adamantan-1-Yl)-2-(Alkyloxy)benzamide Derivatives as Fluorescent Probes for Selective CB2R Targeting

    by Gabriella Rosanna Musillo, Giovanni Graziano, Mariachiara Mammone, Francesco Mastropasqua, Maria Majellaro, Claudia Gioè-Gallo, Jose Brea, Maria Isabel Loza, Anselma Liturri, Morena Miciaccia, et al.

    Background/Objectives: The cannabinoid receptor subtype 2 (CB2R) is an increasingly important therapeutic and diagnostic target because of its involvement in inflammation-associated disorders, including cancer and neurodegenerative diseases. CB2R biology has traditionally been investigated using radioligands, whose broader application is limited by safety, regulatory, operational, and environmental constraints. Fluorescent ligands provide a complementary approach for real-time, high-resolution analysis of receptor expression and dynamics in living systems. This study aimed to develop structurally diverse fluorescent CB2R ligands as molecular tools for investigating receptor localization, trafficking, and signaling across imaging and cell-based platforms. Methods: Probe design was based on two complementary CB2R chemotypes: the 4-oxoquinolinone scaffold of the previously reported fluorescent ligands SM15 and VM7 and the salicylamide scaffold of the reference ligand CC48. These pharmacophores were conjugated to Cyanine 5 (Cy5), Cyanine 7 (Cy7), BODIPY-TR, 7-nitrobenzo-2-oxa-1,3-diazole (NBD), or 7-nitrobenzo-2-selena-1,3-diazole (Se-NBD), generating ligands with emission profiles spanning the green to near-infrared spectral regions. Compound 2, which showed the highest CB2R affinity among the new ligands (Ki = 143.4 nM) and negligible CB1R displacement at 1 µM, was characterized photophysically in organic and aqueous media and evaluated by flow cytometry in MCF7 and PANC-1 cancer cells, which display low and high CB2R expression, respectively. Results: Compound 2 retained nanomolar CB2R affinity and exhibited detectable fluorescence in organic solvents and aqueous buffer down to nanomolar concentrations. In flow cytometry experiments, its concentration-dependent fluorescence differentiated MCF7 from PANC-1 cells. Partial displacement by the CB2R reference ligand 13, particularly in PANC-1 cells, supported a receptor-specific component of the observed labeling. Conclusions: Compound 2 combines CB2R selectivity with robust fluorescence across chemically distinct environments and can distinguish cellular models with different receptor-expression levels. These findings establish compound 2 as a promising tool for CB2R detection and provide a rational basis for developing optimized fluorescent ligands for receptor imaging, target validation, and related translational applications.

  • From Structurally Diverse Sigma-1 (σ1) Receptor Reference Ligands to Live-Cell Probes: Fluorescent Phenoxyalkylpiperidines for the Detection of σ1 Receptor

    by Gabriella Rosanna Musillo, Francesca Serena Abatematteo, Bianca Stiller, Maria Majellaro, Claudia Gioé-Gallo, Sandra Ortigueira, Mauro Niso, Anselma Liturri, Maria Grazia Perrone, Edijs Vavers, et al.

    Sigma-1 (σ1) receptor is increasingly recognized as a ‘pluripotent’ chaperone mainly localized at the mitochondrial-associated endoplasmic reticulum membranes, where it contributes to the regulation of several pathophysiological pathways through a not fully undisclosed interactome. σ1 modulation with small molecules is progressively appearing promising against diverse pathologies that include neurodegenerative, oncology diseases and pain. However, only a deeper understanding of its mechanism of action may lead to σ1 full therapeutic exploitation and specific σ1 fluorescent tracers may help towards this direction. Herein, we fluorescently tagged σ1 reference compounds from four structurally diverse classes. The highest affinity green and red -emitting phenoxyalkylpiperidines 36 and 37 optimally probed σ1 receptor in flow cytometry, producing signals dose-dependently decreased by the σ1 reference (+)-pentazocine. The best-performing ligand 36 allowed the imaging of the σ1 receptor by confocal microscopy in diverse cell lines, appearing as a promising tool for advancing the understanding of σ1 receptor.

  • Open Access

    From 18F-MC225 to Conformationally Free Derivatives

    by Anna Teresa Lisi, Francesco Mastropasqua, Carmen Abate, Marialessandra Contino, Maria Grazia Perrone, Giovanni Graziano, Antonio Carrieri, Nicola Antonio Colabufo, Cristina Filosa, Maria Lucia Calcagni, et al.

    PET radiotracer [18F]MC225 is in two different clinical trials for imaging P-glycoprotein (P-gp) at the BBB level. This radiotracer permits to evaluate both the inset of neurodegenerative pathologies such as MCI, AD, and PD and the drug resistance of antidepressant drugs. Although these studies are ongoing, it is known that in MCI, AD, and PD the activity and expression of P-gp at the BBB level is lower than in healthy subjects, whereas the activity of the same pump is high in human subjects with resistance to antidepressant therapy. This level of P-gp is measured by PET with [18F]MC225 that displayed high brain uptake in neurodegenerative diseases and low brain uptake in subjects with resistance versus several antidepressant drugs. Starting from the mentioned PET radiotracer, a series of conformationally free derivatives have been synthesized testing the role of isosteric substitution in terms of P-gp interactions. Aryl-(oxy)-derivative 2c showed in vitro higher P-gp activity than MC225 (EC50 = 1.8 μM vs EC50 = 6.35 μM). This result has been corroborated with molecular docking, RMSD, and Rog timeline plot. The results disclosed a class of compounds, among them, 2c could be easily [11C]/[18F] radiolabeled for in vivo studies. Considering the lower lipophilicity of 2c than MC225, this ligand could be radiolabeled for imaging P-glycoprotein function and expression that is involved in several heart failures, where a low log P is an important and prelaminar parameter to drug targeting.

  • Dysregulation of Human ClpP Using Small Molecules with Piperazine-Based Scaffold for Diffuse Intrinsic Pontine Glioma Therapy Validated by Patient-Derived Tumor Organoids

    by Morena Miciaccia, Domenico Armenise, Olga Maria Baldelli, Anselma Liturri, Mariachiara Mammone, Giovanni Graziano, Marialessandra Contino, Francesca Rizzo, Paola Loguercio Polosa, Francesco Bruni, et al.

    Diffuse intrinsic pontine glioma (DIPG) is a dismal pediatric brainstem tumor with a median survival of approximately 12 months and no curative treatments. ONC201, the most clinically characterized small-molecule, selectively activates human caseinolytic protease P (hClpP). Guided by X-ray structure of the hClpP:ONC201 complex, piperazine-based derivatives were designed and identified compound 26 (DA29) as a lead. Structural studies confirmed its binding to the enzyme hydrophobic allosteric pocket, a finding consistent with its strong proteolytic activation. Permeability under dynamic flow conditions suggested the ability of 26 (DA29) to cross cellular barriers, indicating potential brain tumor penetration. Mechanistically, 26 (DA29) activates hClpP, displaces hClpX from the hClpXP complex, induces mitochondrial dysfunction and ROS accumulation, and exerts cytotoxic effects in patient-derived DIPG cells and organoids. Notably, unlike ONC201, it does not interact with D2/D3 dopamine receptors. Overall, these findings establish a new structural framework for hClpP-targeted therapies and support further development of 26 (DA29) for DIPG treatment.


  • Open Access

    Dual-Acting Vitamin B 3 -Melanostatin Neuropeptide Hybrids as Potent Modulators of the Dopamine D 2 Receptors with Neuroprotective Activity

    by Beatriz L. Pires-Lima, Sara C. Silva-Reis, Xavier Cruz Correia, Hugo F. Costa-Almeida, Vera M. Costa, Xerardo García-Mera, José Brea, María I. Loza, Marialessandra Contino, Maria Grazia Perrone, et al.

    Parkinson's disease (PD) therapy remains limited by complications of the levodopa regimen, highlighting the need for novel therapeutic strategies to modulate dopaminergic signaling. Melanostatin (MIF-1) has attracted attention as a privileged scaffold for dopamine D2 receptor (D2R) modulation due to its intrinsic positive allosteric modulatory activity, although improved potency and drug-like properties are required for translation. In this work, nicotinic acid (Nic), a vitamer of vitamin B3, was employed as a proline (Pro) bioisostere, generating 12 vitamin B3-MIF-1 hybrids. Nicotinoyl-l-leucylglycinamide (6c) emerged as a lead compound, promoting a 5.11-fold enhancement of dopamine potency at 0.01 nM and displaying neuroprotective activity at 50-100 μM in dopaminergic-differentiated SH-SY5Y cells. Additionally, Pro-to-Nic substitution showed no cytotoxicity in HepG2, reduced P-glycoprotein-mediated efflux, and preserved β-turn conformational propensity, supporting improved oral drug-like properties. Collectively, these findings identify 6c as a dual-acting lead and establish Nic as a privileged Pro surrogate for next-generation MIF-1-based PD therapeutics.

  • Open Access

    Discovery of bridged melanostatin derivatives as potent allosteric modulators of the dopamine D2 receptors with improved permeability

    by Ivo E. Sampaio-Dias, Hugo F. Costa-Almeida, Xavier C. Correia, Beatriz L. Pires-Lima, Marialessandra Contino, Maria Grazia Perrone, Giovanni Graziano, José Brea, María Isabel Loza, Eddy Sotelo, et al.

  • Open Access

    Dysregulation of human ClpP using small molecules with piperazine-based scaffold for diffuse intrinsic pontine glioma therapy validated by patient-derived tumor organoids

    by Antonio Scilimati, Morena Miciaccia, Domenico Armenise, Olga Baldelli, Anselma Liturri, Mariachiara Mammone, Giovanni Graziano, Marialessandra Contino, Francesca Rizzo, Paola Polosa, et al.

    Diffuse intrinsic pontine glioma (DIPG) is an aggressive brainstem tumor affecting children, with median survival under 12 months and no curative treatments. Current therapeutic development centers on ONC201, an imipridone that exhibits clinical activity by selectively activating human caseinolytic protease P ( h ClpP). X-ray analysis of the h ClpP:ONC201 complex offers insights into optimizing the chemical structure of ONC201. Based on this, we designed and synthesized simplified piperazine-based analogs, identifying the polyfunctional chemotype 26 (DA29) through the systematic screening of five new series featuring piperazine-, piperazine-1-one (exocyclic carbonyl), piperazine-1,4-dione (exocyclic carbonyls), piperazine-2-one (endocyclic carbonyl), and piperazine-2,5-dione (endocyclic carbonyls) core scaffolds. The X-ray structure of the h ClpP: 26 (DA29) complex demonstrated a direct binding to the enzyme’s hydrophobic pocket, present at the apical domain, consistent with its strong proteolytic activation. Permeability studies under dynamic flow conditions indicated that 26 (DA29) can cross cellular barriers modeling drug transport, suggesting potential brain tumor penetration. Mechanistic studies showed that 26 (DA29) activates h ClpP, displaces h ClpX from the h ClpXP complex, induces mitochondrial dysfunction and causes ROS accumulation, exerts cytotoxicity and alters lipid profile in patient-derived DIPG cells with validation extended to patient-derived DIPG organoids for personalized medicine. 26 (DA29) does not interact with D2/D3 dopamine receptors as ONC201 does and then is deprived of extrapyramidal collateral effects. Overall, these findings establish a new structural framework for h ClpP-targeted therapy, representing a valuable step towards the development of effective treatments for DIPG.

  • Open Access

    Conformational Restriction of Designer Drugs Reveals Subtype-Selective and Biased CB2 Agonists with Neuroprotective Effects

    by Claudia Gioé-Gallo, Sandra Ortigueira, Rubén Prieto-Díaz, Marialessandra Contino, Jhonny Azuaje, Maria Grazia Perrone, Chiara Riganti, Domenico Alberga, Giuseppe Felice Mangiatordi, Antonio Andújar-Arias, et al.

    This study presents the design, synthesis, and characterization of a novel series of structurally simple, selective, and functionally biased CB2 receptor (CB2R) agonists with potent anti-inflammatory and neuroprotective properties. These compounds were developed using a conformational restriction strategy to abolish CB1R binding, thereby enhancing CB2R selectivity. Pharmacological profiling identified ligands with distinct bias toward β-arrestin, MAPK, and G-protein signaling pathways. The series exhibits favorable drug-like properties, including high BBB permeability, low P-glycoprotein interaction, and microsomal stability. Representative compounds demonstrated neuroprotective activity in mouse primary neuronal assays and significantly reduced ROS and caspase levels in vitro, indicating mitigation of oxidative stress and apoptosis. In a neuron-like SH-SY5Y model expressing pathogenic mutations, they preserved neurite complexity in a CB2R-dependent manner. Collectively, these findings highlight the advantages of conformational restriction in transforming abused promiscuous, neurotoxic ligands into highly selective and efficacious agents for the treatment of neurodegenerative disorders, without CB1R-mediated psychoactive effects.